Claims for Patent: 11,578,044

Summary for Patent: 11,578,044

Title:	Crystalline forms of eravacycline
Abstract:	The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.
Inventor(s):	Danny LaFrance, Philip C. Hogan, Yansheng Liu, Minsheng He, Chi-Li Chen, John Niu
Assignee:	Tetraphase Pharmaceuticals Inc
Application Number:	US17/188,063
Patent Claims:	1. A crystalline form of the bis-HCl salt of a compound represented by Structural Formula 1: wherein the crystalline form is Form J and is characterized by at least three x-ray powder diffraction peaks at 2θ angles selected from the following values ±0.2°: 7.02°, 7.80°, 22.13°, and 23.22°, and wherein the compound of Structural Formula (1) is in the form of a hydrate. 2. The crystalline form of claim 1, wherein the crystalline form is characterized by at least four x-ray powder diffraction peaks at 2θ angles selected from the following values ±0.2°: 7.02°, 7.80°, 10.25°, 22.13°, and 23.22°. 3. The crystalline form of claim 1, wherein the crystalline form is characterized by at least five x-ray powder diffraction peaks at 2θ angles, wherein at least three x-ray powder diffraction peaks are selected from the following values ±0.2°: 7.02°, 7.80°, 22.13°, and 23.22°, and the remainder of the peaks is selected from the following values ±0.2°: 10.25°, 11.00°, 13.29°, 13.60°, 14.98°, 21.92°, 24.02° and 25.28°. 4. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of the following values ±0.2°: 7.02°, 7.80°, 10.25°, 22.13°, and 23.22°. 5. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of the following values ±0.2°: 7.02°, 7.80°, 10.25°, 11.00°, 13.29°, 13.60°, 14.98°, 21.92°, 22.13°, 23.22°, 24.02° and 25.28°. 6. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of the following values ±0.2°: 7.02°, 7.80°, 10.25°, 11.00°, 11.85°, 13.29°, 13.60°, 14.98°, 15.27°, 16.21°, 16.39°, 17.04°, 20.10°, 21.53°, 21.92°, 22.13°, 22.52°, 23.22°, 24.02°, 24.41°, 25.28°, 26.08°, 26.35°, 26.78°, and 27.90°. 7. The crystalline form of claim 1, wherein the crystalline form is characterized by an x-ray powder diffraction pattern in accordance with that depicted in FIG. 7 . 8. A crystalline form of the bis-HCl salt of a compound represented by Structural Formula 1: wherein the crystalline form is Form B and is characterized by at least three x-ray powder diffraction peaks at 2θ angles selected from the following values ±0.2°: 9.19°, 9.66°, 23.32°, and 24.35°, wherein the compound represented by Structural Formula (1) is a co-solvate of water and methanol. 9. The crystalline form of claim 8, wherein the crystalline form is characterized by at least four x-ray powder diffraction peaks at 2θ angles selected from the following values ±0.2°: 9.19°, 9.66°, 17.63°, 23.32°, and 24.35°. 10. The crystalline form of claim 8, wherein the crystalline form is characterized by at least five x-ray powder diffraction peaks at 2θ angles, wherein at least three x-ray powder diffraction peaks are selected from the following values ±0.2°: 9.19°, 9.66°, 23.32°, and 24.35°, and the remainder of the peaks is selected from the following values ±0.2°: 6.10°, 9.48°, 13.05°, 17.63°, 17.77°, 19.94°, and 20.48°. 11. The crystalline form of claim 8, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of the following values ±0.2°: 9.19°, 9.66°, 17.63°, 23.32°, and 24.35°. 12. The crystalline form of claim 8, wherein the crystalline form is characterized by at least five x-ray powder diffraction peaks at 2θ angles, wherein at least three x-ray powder diffraction peaks are selected from the following values ±0.2°: 9.19°, 9.66°, 23.32°, and 24.35°, and the remainder of the peaks is selected from the following values ±0.2°: 6.10°, 9.48°, 13.05°, 17.63°, 17.77°, 19.94°, 20.48°, and 23.87°. 13. The crystalline form of claim 8, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of the following values ±0.2°: 6.10°, 9.19°, 9.48°, 9.66°, 12.08°, 13.05°, 17.63°, 17.77°, 19.54°, 19.94°, 20.48°, 23.32°, 23.87°, and 24.35°. 14. The crystalline form of claim 8, wherein the crystalline form is characterized by an x-ray powder diffraction pattern in accordance with that depicted in any of FIG. 3 . 15. A pharmaceutical composition, comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier. 16. A method for treating or preventing an infection caused by bacteria, the method comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of the crystalline form of claim 1. 17. The method of claim 16, wherein the infection is caused by a Gram-positive bacterium. 18. The method of claim 16, wherein the infection is caused by a Gram-negative bacterium. 19. The method of claim 16, wherein the infection is complicated intra-abdominal infection. 20. The method of claim 19, wherein the subject is a human.